Genomic and Epigenomic Profiling Market Development Driven by Investment in Biotechnology Research and Genomic Screening Programs
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Genomic & Epigenomic Profiling Market Size, Share & Trends Analysis Report, By Type (Genomic Profiling and Epigenomic Profiling), By Application (Clinical Diagnostics, Agriculture & Animal Research, and Drug Discovery & Development), By Technology (NGS, PCR-based, and Microarray), By End-use (Hospitals, Pharmaceuticals, and Research Institutes),-Market Outlook And Industry Analysis 2034"
Genomic & Epigenomic Profiling Market Size is valued at US$ 5.5 Bn in 2024 and is predicted to reach US$ 23.2 Bn by the year 2034 at an 15.8% CAGR during the forecast period for 2025-2034.
Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/3271
Genomic and epigenomic profiling represent sophisticated analytical approaches for investigating the genetic and regulatory architecture of cellular systems. Genomic profiling enables the detection of single-nucleotide variants, insertions and deletions, copy-number variations, and structural rearrangements through techniques such as whole-genome sequencing, targeted sequencing, and genotyping arrays. Epigenomic profiling, on the other hand, assesses chemical and structural modifications that regulate gene expression without altering the DNA sequence itself. The global market for genomic and epigenomic profiling is being propelled by rising prevalence of cancer and rare diseases, continuous technological advancements in sequencing and analytical platforms, and the growing emphasis on personalized medicine. Additionally, sustained investment by pharmaceutical and biotechnology companies in precision therapeutics is expected to further accelerate market expansion over the forecast period.
List of Prominent Players in the Genomic & Epigenomic Profiling Market:
Illumina
Thermo Fisher Scientific
Agilent Technologies
Bio-Rad Laboratories
Roche
Qiagen
PerkinElmer
Pacific Biosciences
BGI Genomics
New England Biolabs
Merck KGaA
Diagenode
Promega Corporation
10x Genomics
Oxford Nanopore Technologies
QIAGEN
Zymo Research
Fulgent Genetics
GENEWIZ
Eurofins Scientific
Invitae
Myriad Genetics
Adaptive Biotechnologies
Guardant Health
Invivoscribe
Others
Read Overview Report- https://www.insightaceanalytic.com/report/genomic-and-epigenomic-profiling-market/3271
Genomic & Epigenomic Profiling Market Report Scope:
Report Attribute
Specifications
Market Size Value In 2024
USD XX Mn
Market Size Value In 2034
USD XX Mn
Growth rate CAGR
CAGR of XX% from 2025 to 2034
Quantitative units
Representation of revenue in US$ Mn, and CAGR from 2025 to 2034
Historic Year
2021 to 2024
Forecast Year
2025-2034
Report coverage
The forecast of revenue, the position of the company, the competitive market statistics, growth prospects, and trends
Segments covered
By Type, By Application, By Technology, By End-use, and By Region
Regional scope
North America; Europe; Asia Pacific; Latin America; Middle East & Africa
Country scope
U.S.; Canada; Germany; The UK; France; Italy; Spain; Rest of Europe; China; Japan; India; South Korea; Southeast Asia; Rest of Asia Pacific; Brazil; Argentina; Mexico; Rest of Latin America; GCC Countries; South Africa; Rest of the Middle East and Africa
Market Dynamics
Drivers:
The global genomic and epigenomic profiling market is being propelled by advancements in high-throughput sequencing technologies, which have enhanced accessibility and significantly reduced costs. The increasing prevalence of complex diseases, including cancer, neurological disorders, and autoimmune conditions, has amplified demand for molecular diagnostics and personalized medicine, driving market growth. Additionally, substantial investments by pharmaceutical and biotechnology firms in the development of targeted therapeutics are accelerating market expansion. The integration of genomic profiling into clinical trials, augmented government funding, and expanded research initiatives further contribute to the sector’s growth trajectory.
Challenges:
Market expansion is challenged by the complexity of managing large-scale genomic and epigenomic datasets, which necessitate advanced computational infrastructure and specialized bioinformatics expertise. Standardizing laboratory protocols and analytical methodologies across diverse platforms remains a significant barrier, potentially affecting data consistency and reliability. Compliance with evolving data privacy regulations, including GDPR, introduces additional complexity for market participants. Translating epigenomic insights into actionable clinical or therapeutic strategies continues to pose scientific challenges, while regulatory uncertainties surrounding novel assays may delay approvals and reimbursement, constraining overall market growth.
Regional Trends:
In 2024, North America dominated the genomic and epigenomic profiling market, driven by a well-established healthcare infrastructure, substantial research and development expenditure, and broad access to cutting-edge technologies. The high prevalence of chronic diseases, including cancer, cardiovascular disorders, and neurological conditions, has further reinforced demand for precision medicine solutions. Genomic and epigenomic profiling is instrumental in enabling patient-specific treatment strategies through detailed genetic insights.
The Asia-Pacific region is projected to achieve the fastest growth over the forecast period, supported by rising healthcare expenditures, increasing awareness of precision medicine, and favorable government initiatives. Countries such as China, Japan, South Korea, and India are investing heavily in genomic research, infrastructure development, and workforce training. Moreover, population-scale genetic screening programs and enhanced access to advanced diagnostic technologies are expected to stimulate innovation and drive sustained market expansion in the region.
Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customization/3271
Recent Developments:
November 2024: The Phase I clinical trials for MyCHELANGELTM, an epigenomic controller that targets uncommon disorders, were successfully completed, according to Omega Therapeutics, indicating advancements in therapeutic epigenetic modulation.
Segmentation of Genomic & Epigenomic Profiling Market-
Genomic & Epigenomic Profiling Market- By Type
Genomic Profiling
Epigenomic Profiling
Genomic & Epigenomic Profiling Market- By Application
Clinical Diagnostics
Agriculture & Animal Research
Drug Discovery & Development
Genomic & Epigenomic Profiling Market- By Technology
NGS
PCR-based
Microarray
Genomic & Epigenomic Profiling Market- By End-use
Hospitals
Pharmaceuticals
Research Institutes
Genomic & Epigenomic Profiling Market- By Region
North America-
The US
Canada
Europe-
Germany
The UK
France
Italy
Spain
Rest of Europe
Asia-Pacific-
China
Japan
India
South Korea
South East Asia
Rest of Asia Pacific
Latin America-
Brazil
Argentina
Mexico
Rest of Latin America
 Middle East & Africa-
GCC Countries
South Africa
Rest of Middle East and Africa
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: https://www.insightaceanalytic.com/
Tel : +1 607 400-7072
Asia: +91 79 72967118
